{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:14:29Z","timestamp":1787876069669,"version":"build-2784847793"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.cca.2023.117244","type":"journal-article","created":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T10:57:33Z","timestamp":1675508253000},"page":"117244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Clinical relevance of plasma EBV DNA as a biomarker for nasopharyngeal carcinoma in non-endemic areas: A multicenter study in southwestern China"],"prefix":"10.1016","volume":"541","author":[{"given":"Qiao","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luona","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianbing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yecai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuju","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiming","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanping","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binwu","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.cca.2023.117244_b0005","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092441","article-title":"Epstein-Barr Virus Mediated Signaling in Nasopharyngeal Carcinoma Carcinogenesis","volume":"12","author":"Richardo","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.cca.2023.117244_b0010","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"10.1016\/j.cca.2023.117244_b0015","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41588-019-0436-5","article-title":"Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma","volume":"51","author":"Xu","year":"2019","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.cca.2023.117244_b0020","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1038\/s41388-020-01631-2","article-title":"The molecular march of primary and recurrent nasopharyngeal carcinoma","volume":"40","author":"Campion","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.cca.2023.117244_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.734293","article-title":"Epstein-Barr Virus Epithelial Cancers-A Comprehensive Understanding to Drive Novel Therapies","volume":"12","author":"Han","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.cca.2023.117244_b0030","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/s41467-022-28479-2","article-title":"EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.cca.2023.117244_b0035","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1038\/s41467-021-25402-z","article-title":"A comprehensive risk score for effective risk stratification and screening of nasopharyngeal carcinoma","volume":"12","author":"Zhou","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.cca.2023.117244_b0040","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1701717","article-title":"Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer","volume":"377","author":"Chan","year":"2017","journal-title":"N Engl J Med"},{"issue":"10192","key":"10.1016\/j.cca.2023.117244_b0045","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.cca.2023.117244_b0050","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/s41416-019-0575-6","article-title":"Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes","volume":"121","author":"Nicholls","year":"2019","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.cca.2023.117244_b0055","doi-asserted-by":"crossref","first-page":"18","DOI":"10.21037\/cco.2016.03.07","article-title":"Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma","volume":"5","author":"Fung","year":"2016","journal-title":"Chin Clin Oncol"},{"issue":"11","key":"10.1016\/j.cca.2023.117244_b0060","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/cac2.12100","article-title":"Clinical utility of Epstein-Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma","volume":"40","author":"Tan","year":"2020","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.cca.2023.117244_b0065","unstructured":"A.B.H.J.F. Fryer, D.E, Wilkinson, P.D. Minor, Collaborative Study Group Collaborative study to evaluate the proposed 1st WHO international standards for Epstein-Barr Virus (EBV) for Nucleic Acid Amplification Technology (NAT)-Based Assays, World Health Organization (2011) https:\/\/apps.who.int\/iris\/handle\/10665\/70781."},{"issue":"6","key":"10.1016\/j.cca.2023.117244_b0070","first-page":"1188","article-title":"Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma","volume":"59","author":"Lo","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.cca.2023.117244_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.104897","article-title":"Prognostic value of the tumor volume reduction rate after neoadjuvant chemotherapy in patients with locoregional advanced nasopharyngeal carcinoma","volume":"110","author":"Yang","year":"2020","journal-title":"Oral Oncol"},{"issue":"8","key":"10.1016\/j.cca.2023.117244_b0080","doi-asserted-by":"crossref","DOI":"10.3390\/biom11081151","article-title":"Epidemiological and Liver Biomarkers Profile of Epstein-Barr Virus Infection and Its Coinfection with Cytomegalovirus in Patients with Hematological Diseases","volume":"11","author":"Ferrari de Freitas","year":"2021","journal-title":"Biomolecules"},{"issue":"8","key":"10.1016\/j.cca.2023.117244_b0085","doi-asserted-by":"crossref","first-page":"e037505","DOI":"10.1136\/bmjopen-2020-037505","article-title":"Global and regional incidence, mortality and disability-adjusted life-years for Epstein-Barr virus-attributable malignancies, 1990\u20132017","volume":"10","author":"Khan","year":"2020","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.cca.2023.117244_b0090","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.7150\/jca.56397","article-title":"Integrating pre- and post-treatment Plasma Epstein-Barr Virus DNA levels for better prognostic prediction of Nasopharyngeal Carcinoma","volume":"12","author":"Li","year":"2021","journal-title":"J Cancer"},{"issue":"9","key":"10.1016\/j.cca.2023.117244_b0095","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/cncr.28564","article-title":"Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China","volume":"120","author":"Ji","year":"2014","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.cca.2023.117244_b0100","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1007\/s12325-020-01461-4","article-title":"A Randomized Controlled Trial on Evaluation of Plasma Epstein-Barr Virus Biomarker for Early Diagnosis in Patients With Nasopharyngeal Carcinoma","volume":"37","author":"Liu","year":"2020","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.cca.2023.117244_b0105","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12935-021-01862-7","article-title":"The diagnostic value of EBV-DNA and EBV-related antibodies detection for nasopharyngeal carcinoma: a meta-analysis","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.cca.2023.117244_b0110","first-page":"1","article-title":"Recent Advances in the Development of Biomarkers and Chemoradiotherapeutic Approaches for Nasopharyngeal Carcinoma","volume":"40","author":"Ma","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"11","key":"10.1016\/j.cca.2023.117244_b0115","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","article-title":"Nasopharyngeal carcinoma: an evolving paradigm","volume":"18","author":"Wong","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.cca.2023.117244_b0120","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1158\/1078-0432.CCR-12-3702","article-title":"An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma","volume":"19","author":"Le","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cca.2023.117244_b0125","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3389\/fonc.2020.01417","article-title":"Prognostication of Half-Life Clearance of Plasma EBV DNA in Previously Untreated Non-metastatic Nasopharyngeal Carcinoma Treated With Radical Intensity-Modulated Radiation Therapy","volume":"10","author":"Chan","year":"2020","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.cca.2023.117244_b0130","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/ijc.33293","article-title":"Clinicopathological and prognostic features of nasopharyngeal carcinoma in children and adolescents: A retrospective study of 196 cases in South China","volume":"148","author":"Zhang","year":"2021","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.cca.2023.117244_b0135","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/cncr.31741","article-title":"Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma","volume":"125","author":"Guo","year":"2019","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.cca.2023.117244_b0140","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/cncr.32770","article-title":"Prognostic potential of liquid biopsy tracking in the posttreatment surveillance of patients with nonmetastatic nasopharyngeal carcinoma","volume":"126","author":"Chen","year":"2020","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.cca.2023.117244_b0145","first-page":"604","article-title":"Cancer Incidence and Mortality in Registration Areas of Sichuan Province, 2016","volume":"34","author":"Cheng","year":"2021","journal-title":"J Cancer Control Treat"},{"issue":"4","key":"10.1016\/j.cca.2023.117244_b0150","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx007","article-title":"Current State of PCR-Based Epstein-Barr Virus DNA Testing for Nasopharyngeal Cancer","volume":"109","author":"Kim","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.cca.2023.117244_b0155","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/cncr.27853","article-title":"Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels","volume":"119","author":"Wang","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.cca.2023.117244_b0160","doi-asserted-by":"crossref","unstructured":"F.P. Chen, L. Lin, J.H. Liang, S.H. Tan, E.H.W. Ong, Y.S. Luo, L. Huang, A.Y.L. Sim, H.T. Wang, T.S. Gao, B. Deng, G.Q. Zhou, J. Kou, M.L.K. Chua, Y. Sun, Development of a risk classification system combining TN-categories and circulating EBV DNA for non-metastatic NPC in 10,149 endemic cases, Ther Adv Med Oncol 13 (2021) 17588359211052417.","DOI":"10.1177\/17588359211052417"},{"issue":"3","key":"10.1016\/j.cca.2023.117244_b0165","first-page":"1046","article-title":"Epstein-Barr virus DNA in serum\/plasma as a tumor marker for nasopharyngeal cancer","volume":"6","author":"Shotelersuk","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.cca.2023.117244_b0170","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMoa032260","article-title":"Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma","volume":"350","author":"Lin","year":"2004","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.cca.2023.117244_b0175","first-page":"2351","article-title":"Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma","volume":"60","author":"Lo","year":"2000","journal-title":"Cancer Res"},{"issue":"21","key":"10.1016\/j.cca.2023.117244_b0180","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/jnci\/94.21.1614","article-title":"Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma","volume":"94","author":"Chan","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.cca.2023.117244_b0185","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.annonc.2020.03.289","article-title":"Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy","volume":"31","author":"Hui","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.cca.2023.117244_b0190","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13027-021-00353-8","article-title":"Circulating cell-free epstein-barr virus DNA levels and clinical features in Moroccan patients with nasopharyngeal carcinoma","volume":"16","author":"Gihbid","year":"2021","journal-title":"Infect Agent Cancer"},{"issue":"6","key":"10.1016\/j.cca.2023.117244_b0195","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/annonc\/mdu117","article-title":"Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma","volume":"25","author":"Leung","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cca.2023.117244_b0200","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejca.2021.05.022","article-title":"A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma","volume":"153","author":"Lee","year":"2021","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.cca.2023.117244_b0205","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1016\/S1470-2045(22)00505-8","article-title":"International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic","volume":"23","author":"Lee","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.cca.2023.117244_b0210","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1002\/ijc.32656","article-title":"Malaysian Nasopharyngeal Carcinoma Study, Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma","volume":"146","author":"Tan","year":"2020","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.cca.2023.117244_b0215","first-page":"59","article-title":"Evaluation of performance and application of three nucleic acid extraction methods for quantification of plasma Epstein-Barr virus DNA","volume":"41","author":"Zheng","year":"2018","journal-title":"Chin J Lab Med"},{"issue":"1","key":"10.1016\/j.cca.2023.117244_b0220","doi-asserted-by":"crossref","first-page":"16510","DOI":"10.1038\/s41598-017-16836-x","article-title":"Graphene oxide enhances the specificity of the polymerase chain reaction by modifying primer-template matching","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"issue":"46","key":"10.1016\/j.cca.2023.117244_b0225","doi-asserted-by":"crossref","first-page":"16254","DOI":"10.1021\/acs.analchem.2c04117","article-title":"Graphene Oxide-Based Highly Sensitive Assay of Circulating MicroRNAs for Early Prediction of the Response to Neoadjuvant Chemotherapy in Breast Cancer","volume":"94","author":"Li","year":"2022","journal-title":"Anal Chem"},{"key":"10.1016\/j.cca.2023.117244_b0230","article-title":"High sensitivity SARS-CoV-2 detection using graphene oxide-multiplex qPCR","volume":"22","author":"Zeng","year":"2022","journal-title":"Anal Chim Acta"},{"issue":"8","key":"10.1016\/j.cca.2023.117244_b9000","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.annonc.2022.04.068","article-title":"Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein-Barr virus DNA in post-treatment plasma","volume":"33","author":"Chan","year":"2022","journal-title":"Ann Oncol"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898123000463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898123000463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:08:19Z","timestamp":1757862499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898123000463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":47,"alternative-id":["S0009898123000463"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2023.117244","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical relevance of plasma EBV DNA as a biomarker for nasopharyngeal carcinoma in non-endemic areas: A multicenter study in southwestern China","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2023.117244","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117244"}}